SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced financial results for the third quarter of fiscal year 2016, which ended March 31, 2016.
Third quarter 2016 revenue of $438.0 million decreased 2% as reported and increased 2% in constant currency from $446.6 million reported in the third quarter a year ago.
Third quarter 2016 revenue of $438.0 million decreased 2% as reported and increased 2% in constant currency from $446.6 million reported in the third quarter a year ago.
